{"id":"W4396587723","doi":"10.1158/1538-7445.sabcs23-po2-18-09","title":"Abstract PO2-18-09: A phase 3 randomized open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy in patients with ER+/HER2– early breast cancer and an intermediate or high risk of recurrence (CAMBRIA 1)","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Cancer; Breast cancer; Endocrine system; Adjuvant; Oncology; Adjuvant therapy; Internal medicine; Open label; Randomized controlled trial; Hormone","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001938963,0.002108256,0.00285521,0.00048764,0.000539922,0.001525969,0.00113463,0.001986415,0.01115333],"category_scores_gemma":[0.001436396,0.0008263662,0.001911581,0.000423748,0.001512275,0.001673882,0.0004538238,0.005490582,0.001989582],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008342814,"about_ca_system_score_gemma":0.001864295,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00101912,"about_ca_topic_score_gemma":0.002642597,"domain_scores_codex":[0.9994766,0.0002757504,0.00002212671,0.00009067572,0.00003564008,0.00009924771],"domain_scores_gemma":[0.9989551,0.0002357601,0.0001737213,0.00007356523,0.0000602546,0.0005014978],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9561769,0.02261799,0.0004575768,0.0003610243,0.0005190724,0.0000436357,0.00005423755,0.0003801831,0.004084707,0.0001245303,0.00146004,0.01372011],"study_design_scores_gemma":[0.9025929,0.09526019,0.0007675639,0.00001423054,0.0001374208,0.00002238027,0.00001663938,0.0003386668,0.0002154295,0.0001065489,0.0005171235,0.00001097709],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9788688,0.002874765,0.001107236,0.001267002,0.0008282263,0.008798151,0.002541356,0.0003090665,0.00340534],"genre_scores_gemma":[0.9652119,0.002519478,0.00340156,0.002949662,0.0007977302,0.01388323,0.003227515,0.00007974635,0.00792912],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01115333,"threshold_uncertainty_score":0.03731161,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05914551455094619,"score_gpt":0.438484531426877,"score_spread":0.3793390168759308,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}